VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
FTREFortrea Holdings Inc.
$17.65$1.7B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksFTRECash Flow

Fortrea Holdings Inc. (FTRE) Cash Flow Statement

5Y historyFree accessUpdated daily

Free cash flow remains highly unstable, swinging from a $262.5 million inflow in 2024Q2 to a $127.1 million deficit in 2025Q1, driven by erratic working capital cycles.

FTRE Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21
Cash from Operations237.7M113.5M262.8M168.4M82.7M169.8M
Operating CF Margin %-4.17%9.75%5.92%2.92%5.55%
Operating CF Growth %4379.6%-56.81%56.06%103.63%-51.3%-
Net Income-446.9M-986.2M-271.5M-25.2M186.2M98M
Depreciation & Amortization58.5M78M98M98M93.6M166.3M
Stock-Based Compensation59.8M74.4M58.4M42.7M25.4M27.5M
Deferred Taxes-25.4M-32M-24.6M-41.6M-16.5M-30.2M
Other Non-Cash Items382.6M864.6M38M67.6M42.2M35.4M
Working Capital Changes185.5M114.7M364.5M26.9M-248.2M-127.2M
Change in Receivables141.4M70.9M309.9M-53.4M-108.4M-187.6M
Change in Inventory000000
Change in Payables-81.5M-109.9M7.2M55.3M24.8M-6.2M
Cash from Investing-1.7M14.4M251.6M-31.8M-54M-26.2M
Capital Expenditures-22.3M-25.2M-25.5M-40.3M-54.4M-26.5M
CapEx % of Revenue0.82%0.93%0.95%1.42%1.92%0.87%
Acquisitions20.6M0276.6M000
Investments------
Other Investing039.6M500K8.5M400K300K
Cash from Financing-164.7M-76.3M-497.8M-140.8M-6.3M-128.5M
Debt Issued (Net)-164.7M-76.3M-482.7M1.62B00
Equity Issued (Net)000000
Dividends Paid000000
Share Repurchases000000
Other Financing00-15.1M-1.76B-6.3M-128.5M
Net Change in Cash45.9M56.1M9.9M-1.8M15.8M14.3M
Free Cash Flow215.4M88.3M237.3M128.1M28.3M143.3M
FCF Margin %7.95%3.24%8.8%4.51%1%4.69%
FCF Growth %48.45%-62.79%85.25%352.65%-80.25%-
FCF per Share2.360.972.651.440.321.62
FCF Conversion (FCF/Net Income)-0.48x-0.12x-0.80x-6.68x0.44x1.73x
Interest Paid000000
Taxes Paid000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Persistent operating cash volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Obscured by Volatility

As reported in recent financial filings, the relationship between net income and operating cash flow remains highly erratic, with OCF/NI ratios frequently reaching extreme negative values, such as the -5.46 observed in 2025Q3, indicating that accounting losses are not currently reflective of underlying cash generation.

The significant divergence between net income and operating cash flow suggests that non-cash charges and working capital swings are heavily distorting the company's reported profitability. Investors should monitor whether this disconnect is a temporary byproduct of the spin-off or a sign of persistent difficulty in converting service revenue into actual cash.

Free Cash Flow Trajectory Uncertainty

Based on the provided cash flow data, free cash flow has exhibited extreme instability, swinging from a peak of $262.5 million in 2024Q2 to a deficit of $127.1 million in 2025Q1, highlighting the company's struggle to maintain consistent cash generation as an independent entity.

The lack of a stable FCF trend suggests that the business model is currently sensitive to operational disruptions that impact cash timing. Without a predictable FCF margin, the company may face challenges in funding its own growth or servicing debt obligations without relying on external financing.

Working Capital Swings Drive Liquidity

According to quarterly cash flow statements, working capital changes have been the primary driver of cash flow volatility, evidenced by a massive $350.7 million inflow in 2024Q2 followed by an $88.6 million outflow in 2025Q1, suggesting highly inconsistent collection and payment cycles.

These dramatic fluctuations in working capital imply that the company's cash position is highly dependent on the timing of large project milestones or sponsor payments. Such volatility warrants further investigation into whether these shifts represent structural inefficiencies in the billing process or merely the lumpy nature of clinical trial contracts.

Hidden Cash Flow Distortions Identified

Based on an analysis of the cash flow statement, the company's reported figures are significantly impacted by stock-based compensation and recurring depreciation, with SBC expenses reaching $22.7 million in 2025Q2, which effectively masks the true cash cost of maintaining the company's human capital.

The reliance on SBC as a significant non-cash add-back suggests that the company's operating cash flow may be overstated relative to the actual economic cost of its workforce. Analysts should be cautious, as these adjustments may obscure the true cash-burn rate required to retain specialized clinical staff in a competitive labor market.

FTRE — Frequently Asked Questions

Quick answers to the most common questions about buying FTRE stock.

How much cash does Fortrea Holdings Inc. (FTRE) generate from operations?

Fortrea Holdings Inc. (FTRE) generated $113.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Fortrea Holdings Inc.'s free cash flow?

Fortrea Holdings Inc. (FTRE) generated $88.3M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Fortrea Holdings Inc.'s capital expenditure (CapEx)?

Fortrea Holdings Inc. (FTRE) spent $25.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.